1. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C‐SCAPE study. Issue 5 (14th March 2018) Authors: Brown, A.; Hézode, C.; Zuckerman, E.; Foster, G. R.; Zekry, A.; Roberts, S. K.; Lahser, F.; Durkan, C.; Badshah, C.; Zhang, B.; Robertson, M.; Wahl, J.; Barr, E.; Haber, B. Journal: Journal of viral hepatitis Issue: Volume 25:Issue 5(2018) Page Start: 457 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗